Connect Biopharma Holdings Limited — Form 6-K Summary
Reporting period: Form 6-K furnished May 3, 2022, for the month of May 2022. The filing reports top-line 12-week results from the Phase 2 CBP-307CN002 trial in adults with moderate-to-severe ulcerative colitis.
Business Context and Trial Overview
CBP-307 is a once-daily oral selective sphingosine 1-phosphate receptor modulator. The randomized, double-blind, placebo-controlled trial enrolled 145 patients at more than 60 sites in four countries: 39 received 0.1 mg, 53 received 0.2 mg, and 53 received placebo. The Company identified CBP-201, an IL-4 receptor alpha antagonist, as its lead program and intends to focus resources on CBP-201 while exploring partnerships for CBP-307.
Key Results and Metrics
- Primary endpoint: At Week 12, LS mean change from baseline in adapted Mayo Score was -2.65 for CBP-307 0.2 mg versus -2.01 for placebo; the difference was not statistically significant (p=0.103).
- Clinical remission, adapted Mayo Score: 28.3% for CBP-307 0.2 mg versus 9.6% for placebo (difference 18.7 percentage points; p=0.016).
- Clinical remission, complete Mayo Score: 18.9% versus 5.8% (difference 13.1 percentage points; p=0.044).
- Complete Mayo Score change: LS mean change was -3.67 for CBP-307 0.2 mg versus -2.74 for placebo (p=0.050).
- Clinical response, complete Mayo Score: 52.8% versus 30.8% (p=0.023).
- Clinical response, adapted Mayo Score: 54.7% versus 36.5% (p=0.064), which did not meet statistical significance.
- CBP-307 0.1 mg: Remission and response results were generally numerically better than placebo in some measures but did not meet statistical significance; adapted-score response was 33.3% versus 36.5% for placebo (p=0.784).
- Pharmacodynamic activity: Mean lymphocyte reductions were 51.3% for 0.2 mg and 42.7% for 0.1 mg, with mean absolute counts reduced to approximately 0.8 and 1.0 x 109/L, respectively, at Week 12.
- Safety: Drug-related treatment-emergent adverse events occurred in 66.0% of patients receiving 0.2 mg, 59.0% receiving 0.1 mg, and 38.5% receiving placebo.
- Serious and severe adverse events: Grade 3 or higher events occurred in 7.5% of the 0.2 mg group and 7.7% of placebo; serious events occurred in 3.8% and 5.8%, respectively. The 0.1 mg group had rates of 25.6% and 15.4%, respectively.
- Deaths and notable safety events: No deaths or cases of progressive multifocal leukoencephalopathy were reported.
Financial Position and Liquidity
This Form 6-K does not provide revenue, net income, cash flow, margin, debt, cash balance, liquidity, or other financial statement metrics. The filing is focused on clinical trial results and corporate updates.
Material Changes and Outlook
- The 0.2 mg dose achieved statistically significant improvements in several secondary efficacy endpoints, although the primary endpoint did not reach statistical significance.
- The Company stated that CBP-307 warrants further clinical development based on the efficacy and safety findings.
- The Company plans to focus resources on CBP-201 and engage in partnership discussions regarding future CBP-307 development.
- No specific financial guidance, development timeline, partnering terms, or additional quantitative outlook was provided.
Risks, Contingencies, and Unusual Items
CBP-307 remains an investigational product and has not been approved for commercial use. The filing cautions that development plans, product potential, partnership activities, and future clinical outcomes are forward-looking and subject to risks described in the Company’s SEC filings, including its 2021 Form 20-F filed March 31, 2022. The 0.1 mg arm showed higher rates of Grade 3 or higher and serious adverse events than the 0.2 mg and placebo groups, warranting attention in further development.
Investor Verification Checklist
- Verify the full statistical analysis, patient disposition, confidence intervals, multiplicity adjustments, and detailed adverse-event tables in the exhibits and subsequent filings.
- Assess whether the non-significant primary endpoint affects the regulatory and development path for CBP-307.
- Review the durability and maintenance-treatment results, since this update reports Week 12 top-line data from an induction and maintenance study.
- Monitor any partnership announcements, development decisions, or changes in resource allocation between CBP-307 and CBP-201.
- Consult the Company’s latest financial filings for cash runway, financing needs, operating expenses, debt, and liquidity, which are not provided in this Form 6-K.